UriVArx^® was evaluated in two clinical studies. Both studies confirmed the safety and the benefit of UriVArx^® in supporting healthy bladder function and normal urinary frequency.

The first study compared the efficacy of crataeva and horsetail to UriVarx^®. UriVArx^® was proven to be more effective in reducing the frequency of daily urination and superior in reducing nocturia compared to crataeva and horsetail after one month of treatment.

UriVArx^® was evaluated in an in an 8-week, double-blind, randomized, placebo-controlled, clinical study. UriVArx^® was assessed in participants to determine the effect on urinary frequency and urgency. Data was collected at 2, 4, and 8 weeks. The primary outcome measure was self-reported urinary frequency defined as the number of voluntary diurnal and/ or nocturnal micturitions. Reported baseline measurements were similar between groups. At week 8, urinary frequency during the day was significantly lower in subjects administered UriVArx^® compared to placebo (Figure 3). Similarly, episodes of nocturia and urgency were significantly fewer versus placebo (Figures 4 & 5). Significant improvements in quality of life were reported at end of study in comparison to placebo.

There were no serious side effects reported, and 84% of participants confirmed they had benefited from treatment.*

There were no adverse events leading to discontinuation.